A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma

Trial Profile

A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PIANO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2015 Accrual till date is 4% according to United Kingdom Clinical Research Network record.
    • 09 Dec 2015 Planned End Date changed from 1 May 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top